share_log

Deep Medicine Acquisition Corp. (NASDAQ:DMAQ) Sees Significant Increase in Short Interest

Deep Medicine Acquisition Corp. (NASDAQ:DMAQ) Sees Significant Increase in Short Interest

深度医药收购公司(纳斯达克代码:DMAQ)在空头股数的持股大幅增加
kopsource ·  2022/10/05 08:52

Deep Medicine Acquisition Corp. (NASDAQ:DMAQ – Get Rating) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 2,600 shares, an increase of 8.3% from the August 31st total of 2,400 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 22,500 shares, the short-interest ratio is presently 0.1 days.

深度医药收购公司(纳斯达克代码:dmaq-Get Rating)是空头股数9月份大幅增长的目标。截至9月15日,空头股数共有2,600股,比8月31日的2,400股增加了8.3%。该公司约0.0%的股份被卖空。以日均成交量22,500股计算,目前短息比率为0.1天。

Deep Medicine Acquisition Price Performance

深度医疗收购价格表现

Shares of DMAQ opened at $10.08 on Wednesday. Deep Medicine Acquisition has a 1 year low of $9.70 and a 1 year high of $10.99. The company's fifty day moving average is $10.05 and its two-hundred day moving average is $10.01.

周三,DMAQ的股价开盘报10.08美元。深度医药收购的一年低点为9.70美元,一年高位为10.99美元。该公司的50日移动均线切入位在10.05美元,200日移动均线切入位在10.01美元。

Get
到达
Deep Medicine Acquisition
深度医学收购
alerts:
警报:

Institutional Trading of Deep Medicine Acquisition

深度医药收购的制度性交易

Hedge funds and other institutional investors have recently made changes to their positions in the company. Karpus Management Inc. acquired a new stake in Deep Medicine Acquisition in the fourth quarter valued at about $19,801,000. Saba Capital Management L.P. acquired a new stake in shares of Deep Medicine Acquisition in the 4th quarter valued at approximately $8,908,000. Beryl Capital Management LLC purchased a new stake in shares of Deep Medicine Acquisition in the fourth quarter valued at approximately $6,012,000. Oaktree Capital Management LP acquired a new position in Deep Medicine Acquisition during the fourth quarter worth $4,173,000. Finally, Hsbc Holdings PLC purchased a new position in Deep Medicine Acquisition in the first quarter worth $2,976,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

对冲基金和其他机构投资者最近对他们在该公司的头寸进行了调整。Karpus Management Inc.在第四季度收购了Deep Medicine收购的新股份,价值约为19,801,000美元。萨巴资本管理公司在第四季度收购了深度医药收购公司的新股份,价值约为8,908,000美元。贝丽尔资本管理有限责任公司在第四季度购买了深度医药收购公司的新股份,价值约为601.2万美元。橡树资本管理有限公司在第四季度收购了价值4,173,000美元的Deep Medicine收购的新头寸。最后,汇丰控股在第一季度购买了深医收购的新头寸,价值297.6万美元。对冲基金和其他机构投资者持有该公司89.62%的股票。

About Deep Medicine Acquisition

关于深度医学的收购

(Get Rating)
(获取评级)

Deep Medicine Acquisition Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It focuses on identifying businesses in the healthcare industry.

深度医药收购公司没有重大业务。公司拟与一家或多家企业进行合并、资本换股、资产收购、股票购买、重组或类似的业务合并。它专注于识别医疗保健行业的企业。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on Deep Medicine Acquisition (DMAQ)
  • Don't Give Up on These Q3 Losers
  • The Anatomy of a Great Pension Plan
  • 3 Safe Earnings Plays for a Risk-Off Market
  • Tyson Foods Takes a Lickin' and Keeps on Tickin' Lower
  • Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
  • 免费获取StockNews.com关于深度医学收购的研究报告(DMAQ)
  • 不要放弃这些第三季度的失败者
  • 一个伟大的养老金计划的剖析
  • 避险市场的三大安全收益
  • 泰森食品股价下跌,继续走低
  • 小盘股Catalyst Pharma是市场上价格表现最好的公司之一

Receive News & Ratings for Deep Medicine Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deep Medicine Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.

接受深度医疗收购日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收最新新闻和分析师对深度医药收购和相关公司评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发